LATIN AMERICA OPHTHALMIC DRUGS MARKET 2023-2030

Lifesciences | Pharmaceuticals

LATIN AMERICA OPHTHALMIC DRUGS MARKET 2023-2030

Market by Type, Condition, Therapeutic Type, Delivery Method, Channel, and Country Outlook | Forecast 2023-2030

Request For Customization

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

Triton’s research report studies that the Latin American ophthalmic drugs market is anticipated to rise at 7.41% CAGR during the forecast period 2023-2030.


Report scope can be customized per your requirements - Request Free Sample Report

The countries examined in the studied region include:

•        Brazil

•        Mexico

•        Rest of Latin America

Multiple factors, such as expansion in healthcare infrastructure, an increase in the number of eye disorders among the adult population, and awareness regarding eye health drive the growth of the ophthalmic drugs market in Latin America. There is a significant rise in the use of ophthalmic drug products to prevent blindness and vision impairment. The established pharmaceutical companies, as well as new entrants, take the lead to develop a streamlined ophthalmic drug delivery system and enhance treatment efficacy, especially among the middle-class population.

Brazil leads with the highest share in the Latin American ophthalmic drugs market. The regulatory norms by the National Health Surveillance Agency (ANVISA) ensure that ophthalmic drug products meet high quality and safety standards. Additionally, the demographic transitions and developments in the healthcare sector propel the growth of the ophthalmic drugs market. The use of these drugs is mainly due to the rise in the aging population and their eye disorders.

In Mexico, the ophthalmic drugs market is also experiencing innovation due to mergers and collaborations. This presents substantial growth opportunities to develop eye care products that are safe and efficient. The inventions and recent developments regarding eye therapies and cataract treatments also drive the use of ophthalmic drugs. The government, therefore, caters to the diverse eye care needs of the population by increasing the expenditure on healthcare.

Since COVID-19, online pharmacies have been one of the convenient channels for ophthalmic drug delivery systems. The growth of such virtual platforms enables patients to get access to 24/7 treatment facilities within the comfort of their homes, preventing high medication costs. The segments of the studied market include type, delivery method, therapeutic type, condition, and channel. The channel type segment comprises Hospital Pharmacies, drugs, online pharmacies, and other distribution channels.

The leading enterprises in the ophthalmic drugs market are Bausch Health Companies Inc, AbbVie Inc, Pfizer Inc, Sun Pharmaceutical Industries Ltd, Johnson & Johnson, Thea Pharma Inc, Novartis AG, Accutome Inc, Regeneron Pharmaceuticals Inc, and Genentech Inc.

Bausch Health Companies Inc is a pharmaceutical company based in Canada that manufactures and develops both branded as wells as generic pharmaceutical products. Its portfolio includes generics, neurology, dentistry, gastrointestinal, dermatology products, international pharmaceuticals, etc. The company markets its products across 90 countries across multiple regions, including Latin America, Europe, Asia-Pacific, and Africa.


KEY DELIVERABLES OF THE REPORT:

      Market CAGR during the forecasting years 2023-2030

      Detailed data highlighting key insights, industry components, and market strategies

      Comprehensive information and estimation of the ophthalmic drugs market revenue growth in Latin America and its influence on the parent market

      In-depth study of forthcoming trends in consumer behavioral patterns

      A meticulous analysis of the competitive landscape, vendor scorecard, and Porter’s Five Forces

      A wide-ranging study of factors that will challenge the Latin America ophthalmic drugs market’s growth during the upcoming years

Want to get specific insights? Our team of analysts can customize this report based on your preferences. Connect with us here.

Related Reports

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027
Lifesciences

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027

Market By Type, Application, E ..

VIEW REPORT
ASIA PACIFIC BIOCHIPS MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOCHIPS MARKET 2019-2027

Market By Type, Substrate Mate ..

VIEW REPORT
ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027

Market By Device Type, Therape ..

VIEW REPORT
ASIA PACIFIC DNA VACCINES MARKET 2019-2027
Lifesciences

ASIA PACIFIC DNA VACCINES MARKET 2019-2027

Market By Type, Application, T ..

VIEW REPORT
ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027
Lifesciences

ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027

Market By Technology, Applicat ..

VIEW REPORT
ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028
Lifesciences

ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028

Market By Application, Type, E ..

VIEW REPORT
ASIA-PACIFIC AMNIOTIC MEMBRANE MARKET 2022-2028
Lifesciences

ASIA-PACIFIC AMNIOTIC MEMBRANE MARKET 2022-2028

Market by Type, Application, E ..

VIEW REPORT

Table of Content

1.    LATIN AMERICA OPHTHALMIC DRUGS MARKET - SUMMARY

2.    INDUSTRY OUTLOOK

2.1. TECHNOLOGY SNAPSHOT

2.2. IMPACT ANALYSIS ON THE OPHTHALMIC DRUGS MARKET

2.2.1. COVID-19 IMPACT ON THE OPHTHALMIC DRUGS MARKET

2.3. PORTERS FIVE FORCES ANALYSIS

2.3.1. THREAT OF NEW ENTRANTS

2.3.2. THREAT OF SUBSTITUTES

2.3.3. BARGAINING POWER OF BUYERS

2.3.4. BARGAINING POWER OF SUPPLIERS

2.3.5. THREAT OF COMPETITIVE RIVALRY

2.4. MARKET MATURITY ANALYSIS

2.5. REGULATORY FRAMEWORK

2.6. KEY BUYING IMPACT ANALYSIS

2.7. KEY MARKET STRATEGIES

2.7.1. COLLABORATIONS

2.7.2. PRODUCT LAUNCHES

2.7.3. MERGERS & ACQUISITIONS

2.8. MARKET DRIVERS

2.8.1. AGING POPULATION VULNERABLE TO EYE DISORDERS

2.8.2. PROGRESS IN DRUG DELIVERY TECHNOLOGIES

2.8.3. ESCALATING INCIDENCE OF OCULAR DISEASES

2.8.4. REIMBURSEMENT POLICIES BY HEALTHCARE SYSTEMS

2.9. MARKET CHALLENGES

2.9.1. CHALLENGING TIMELINES FOR PRODUCT APPROVAL

2.9.2. ADVERSE EFFECTS ASSOCIATED WITH OPHTHALMIC DRUG USAGE

2.10. MARKET OPPORTUNITIES

2.10.1. SURGE IN INTEREST REGARDING TOPICALLY ADMINISTERED OPHTHALMIC DRUGS

2.10.2. INCREASE IN APPROVALS FOR INNOVATIVE OPHTHALMIC THERAPIES

2.11. ANALYST PERSPECTIVE

3.    LATIN AMERICA OPHTHALMIC DRUGS MARKET – BY TYPE

3.1. PRESCRIPTION DRUGS

3.2. OVER-THE-COUNTER DRUGS

4.    LATIN AMERICA OPHTHALMIC DRUGS MARKET – BY CONDITION

4.1. DRY EYE

4.2. GLAUCOMA

4.3. INFECTION/INFLAMMATION/ALLERGIES

4.4. RETINAL DISORDER

4.4.1. WET-AGE RELATED MACULAR DEGENERATION

4.4.2. DRY-AGE RELATED MACULAR DEGENERATION

4.4.3. DIABETIC RETINOPATHY

4.4.4. OTHER RETINAL DISORDERS

4.5. OTHER CONDITIONS

5.    LATIN AMERICA OPHTHALMIC DRUGS MARKET – BY THERAPEUTIC TYPE

5.1. ANTI-GLAUCOMA

5.2. ANTI-INFECTION

5.3. ANTI-INFLAMMATORY

5.4. ANTI-ALLERGY

5.5. OTHER THERAPEUTIC TYPES

6.    LATIN AMERICA OPHTHALMIC DRUGS MARKET – BY DELIVERY METHOD

6.1. GELS

6.2. EYE SOLUTIONS & SUSPENSIONS

6.3. CAPSULES & TABLETS

6.4. EYE DROPS

6.5. OINTMENTS

7.    LATIN AMERICA OPHTHALMIC DRUGS MARKET – BY CHANNEL

7.1. HOSPITAL PHARMACIES

7.2. DRUG STORES

7.3. ONLINE PHARMACIES

7.4. OTHER CHANNELS

8.    LATIN AMERICA OPHTHALMIC DRUGS MARKET – COUNTRY OUTLOOK

8.1. BRAZIL

8.1.1. BRAZIL OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

8.2. MEXICO

8.2.1. MEXICO OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

8.3. REST OF LATIN AMERICA

8.3.1. REST OF LATIN AMERICA OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

9.    COMPETITIVE LANDSCAPE

9.1. ABBVIE INC

9.1.1. OVERVIEW

9.1.2. PRODUCT PORTFOLIO

9.1.3. KEY STRENGTHS

9.1.4. KEY CHALLENGES

9.2. BAUSCH HEALTH COMPANIES INC

9.2.1. OVERVIEW

9.2.2. PRODUCT PORTFOLIO

9.2.3. KEY STRENGTHS

9.2.4. KEY CHALLENGES

9.3. JOHNSON & JOHNSON

9.3.1. OVERVIEW

9.3.2. PRODUCT PORTFOLIO

9.3.3. KEY STRENGTHS

9.3.4. KEY CHALLENGES

9.4. NOVARTIS AG

9.4.1. OVERVIEW

9.4.2. PRODUCT PORTFOLIO

9.4.3. KEY STRENGTHS

9.4.4. KEY CHALLENGES

9.5. REGENERON PHARMACEUTICALS INC

9.5.1. OVERVIEW

9.5.2. PRODUCT PORTFOLIO

9.5.3. KEY STRENGTHS

9.5.4. KEY CHALLENGES

9.6. SUN PHARMACEUTICAL INDUSTRIES LTD

9.6.1. OVERVIEW

9.6.2. PRODUCT PORTFOLIO

9.6.3. KEY STRENGTHS

9.6.4. KEY CHALLENGES

9.7. ACCUTOME INC

9.7.1. OVERVIEW

9.7.2. PRODUCT PORTFOLIO

9.7.3. KEY STRENGTHS

9.7.4. KEY CHALLENGES

9.8. GENENTECH INC

9.8.1. OVERVIEW

9.8.2. PRODUCT PORTFOLIO

9.8.3. KEY STRENGTHS

9.8.4. KEY CHALLENGES

9.9. THEA PHARMA INC

9.9.1. OVERVIEW

9.9.2. PRODUCT PORTFOLIO

9.9.3. KEY STRENGTHS

9.9.4. KEY CHALLENGES

9.10. PFIZER INC

9.10.1. OVERVIEW

9.10.2. PRODUCT PORTFOLIO

9.10.3. KEY STRENGTHS

9.10.4. KEY CHALLENGES

10. RESEARCH METHODOLOGY & SCOPE

10.1. RESEARCH SCOPE & DELIVERABLES

10.2. SOURCES OF DATA

10.3. RESEARCH METHODOLOGY

List of Tables

TABLE 1: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY COUNTRY, 2023-2030 (IN $ MILLION)

TABLE 2: REGULATORY FRAMEWORK

TABLE 3: LIST OF COLLABORATIONS

TABLE 4: LIST OF PRODUCT LAUNCHES

TABLE 5: LIST OF MERGERS & ACQUISITIONS

TABLE 6: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY COUNTRY OUTLOOK, 2023-2030 (IN $ MILLION)

TABLE 7: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY TYPE, 2023-2030 (IN $ MILLION)

TABLE 8: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY CONDITION, 2023-2030 (IN $ MILLION)

TABLE 9: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, 2023-2030 (IN $ MILLION)

TABLE 10: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC TYPE, 2023-2030 (IN $ MILLION)

TABLE 11: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY DELIVERY METHOD, 2023-2030 (IN $ MILLION)

TABLE 12: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY CHANNEL, 2023-2030 (IN $ MILLION)

List of Figures

FIGURE 1: TECHNOLOGY SNAPSHOT

FIGURE 2: MARKET MATURITY ANALYSIS

FIGURE 3: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY TYPE, 2022 & 2030 (IN %)

FIGURE 4: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY PRESCRIPTION DRUGS, 2023-2030 (IN $ MILLION)

FIGURE 5: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY OVER-THE-COUNTER DRUGS, 2023-2030 (IN $ MILLION)

FIGURE 6: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY CONDITION, 2022 & 2030 (IN %)

FIGURE 7: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY DRY EYE, 2023-2030 (IN $ MILLION)

FIGURE 8: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY GLAUCOMA, 2023-2030 (IN $ MILLION)

FIGURE 9: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY INFECTION/INFLAMMATION/ALLERGIES, 2023-2030 (IN $ MILLION)

FIGURE 10: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, 2023-2030 (IN $ MILLION)

FIGURE 11: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, 2022 & 2030 (IN %)

FIGURE 12: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY WET AGE-RELATED MACULAR DEGENERATION, 2023-2030 (IN $ MILLION)

FIGURE 13: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY DRY AGE-RELATED MACULAR DEGENERATION, 2023-2030 (IN $ MILLION)

FIGURE 14: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY DIABETIC RETINOPATHY, 2023-2030 (IN $ MILLION)

FIGURE 15: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY OTHER RETINAL DISORDERS, 2023-2030 (IN $ MILLION)

FIGURE 16: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY OTHER CONDITIONS, 2023-2030 (IN $ MILLION)

FIGURE 17: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC TYPE, 2022 & 2030 (IN %)

FIGURE 18: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY ANTI-GLAUCOMA, 2023-2030 (IN $ MILLION)

FIGURE 19: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY ANTI-INFECTION, 2023-2030 (IN $ MILLION)

FIGURE 20: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY ANTI-INFLAMMATORY, 2023-2030 (IN $ MILLION)

FIGURE 21: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY ANTI-ALLERGY, 2023-2030 (IN $ MILLION)

FIGURE 22: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY OTHER THERAPEUTIC TYPES, 2023-2030 (IN $ MILLION)

FIGURE 23: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY DELIVERY METHOD, 2022 & 2030 (IN %)

FIGURE 24: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY GELS, 2023-2030 (IN $ MILLION)

FIGURE 25: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY EYE SOLUTIONS & SUSPENSIONS, 2023-2030 (IN $ MILLION)

FIGURE 26: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY CAPSULES & TABLETS, 2023-2030 (IN $ MILLION)

FIGURE 27: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY EYE DROPS, 2023-2030 (IN $ MILLION)

FIGURE 28: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY OINTMENTS, 2023-2030 (IN $ MILLION)

FIGURE 29: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY CHANNEL, 2022 & 2030 (IN %)

FIGURE 30: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY HOSPITAL PHARMACIES, 2023-2030 (IN $ MILLION)

FIGURE 31: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY DRUG STORES, 2023-2030 (IN $ MILLION)

FIGURE 32: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY ONLINE PHARMACIES, 2023-2030 (IN $ MILLION)

FIGURE 33: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY OTHER CHANNELS, 2023-2030 (IN $ MILLION)

FIGURE 34: LATIN AMERICA OPHTHALMIC DRUGS MARKET, BY COUNTRY OUTLOOK, 2022 & 2030 (IN %)

FIGURE 35: BRAZIL OPHTHALMIC DRUGS MARKET, 2023-2030 (IN $ MILLION)

FIGURE 36: MEXICO OPHTHALMIC DRUGS MARKET, 2023-2030 (IN $ MILLION)

FIGURE 37: REST OF LATIN AMERICA OPHTHALMIC DRUGS MARKET, 2023-2030 (IN $ MILLION)

Purchase Options

  • Licence Type
  • Price
  • User/Sharing
  • Printing
  • Delivery Formats
  • Free customization (Pre-sale)
  • Analyst hour support (Post Sale)
  • Customized notification for newly published report
  • Free report on update (within 180 days)

Single User PDF

$1,500.00

  • User/Sharing
  • Restricted to one authorized user
  • Printing
  • Not printable
  • Delivery Formats
  • Pdf
  • Free customization (Pre-sale)
  • 10% Free customization
  • Analyst hour support (Post Sale)
  • 3 hours
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Enterprise Online/PDF

$2,200.00

  • User/Sharing
  • Unlimited
  • Printing
  • Unlimited
  • Delivery Formats
  • Pdf and market estimation excel
  • Free customization (Pre-sale)
  • 20% Free customization
  • Analyst hour support (Post Sale)
  • 8 hour
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Request free Sample

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying